Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $77.01 million. The enterprise value is $92.40 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.61 million shares outstanding. The number of shares has increased by 18.30% in one year.
| Current Share Class | 62.61M |
| Shares Outstanding | 62.61M |
| Shares Change (YoY) | +18.30% |
| Shares Change (QoQ) | +11.00% |
| Owned by Insiders (%) | 13.25% |
| Owned by Institutions (%) | 27.36% |
| Float | 54.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.84 |
| Forward PS | 2.34 |
| PB Ratio | 4.99 |
| P/TBV Ratio | 7.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 1.85.
| Current Ratio | 2.61 |
| Quick Ratio | 1.98 |
| Debt / Equity | 1.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.02 |
Financial Efficiency
Return on equity (ROE) is -96.25% and return on invested capital (ROIC) is -25.65%.
| Return on Equity (ROE) | -96.25% |
| Return on Assets (ROA) | -20.46% |
| Return on Invested Capital (ROIC) | -25.65% |
| Return on Capital Employed (ROCE) | -39.02% |
| Revenue Per Employee | $237,129 |
| Profits Per Employee | -$108,111 |
| Employee Count | 149 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 3.22 |
Taxes
| Income Tax | -1.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.69% in the last 52 weeks. The beta is 1.05, so Cytosorbents's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +57.69% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 65.44 |
| Average Volume (20 Days) | 109,445 |
Short Selling Information
The latest short interest is 1.43 million, so 2.29% of the outstanding shares have been sold short.
| Short Interest | 1.43M |
| Short Previous Month | 1.46M |
| Short % of Shares Out | 2.29% |
| Short % of Float | 2.64% |
| Short Ratio (days to cover) | 16.43 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $35.33 million and -$16.11 million in losses. Loss per share was -$0.29.
| Revenue | 35.33M |
| Gross Profit | 24.46M |
| Operating Income | -16.02M |
| Pretax Income | -28.35M |
| Net Income | -16.11M |
| EBITDA | -14.48M |
| EBIT | -16.02M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $11.59 million in cash and $26.98 million in debt, giving a net cash position of -$15.39 million or -$0.25 per share.
| Cash & Cash Equivalents | 11.59M |
| Total Debt | 26.98M |
| Net Cash | -15.39M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | 14.54M |
| Book Value Per Share | 0.23 |
| Working Capital | 15.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.06 million and capital expenditures -$241,273, giving a free cash flow of -$13.30 million.
| Operating Cash Flow | -13.06M |
| Capital Expenditures | -241,273 |
| Free Cash Flow | -13.30M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
Gross margin is 69.23%, with operating and profit margins of -45.33% and -45.59%.
| Gross Margin | 69.23% |
| Operating Margin | -45.33% |
| Pretax Margin | -50.38% |
| Profit Margin | -45.59% |
| EBITDA Margin | -40.97% |
| EBIT Margin | -45.33% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.30% |
| Shareholder Yield | -18.30% |
| Earnings Yield | -20.92% |
| FCF Yield | -17.28% |
Analyst Forecast
The average price target for Cytosorbents is $5.50, which is 347.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.50 |
| Price Target Difference | 347.15% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 30.93% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
Cytosorbents has an Altman Z-Score of -7.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.49 |
| Piotroski F-Score | 3 |